Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study
dc.contributor.author | Au, H. | |
dc.contributor.author | Eiermann, W. | |
dc.contributor.author | Robert, N. | |
dc.contributor.author | Pienkowski, T. | |
dc.contributor.author | Crown, J. | |
dc.contributor.author | Martin, M. | |
dc.contributor.author | Pawlicki, M. | |
dc.contributor.author | Chan, Arlene | |
dc.contributor.author | Mackey, J. | |
dc.contributor.author | Glaspy, J. | |
dc.contributor.author | Pintér, T. | |
dc.contributor.author | Liu, M. | |
dc.contributor.author | Fornander, T. | |
dc.contributor.author | Sehdev, S. | |
dc.contributor.author | Ferrero, J. | |
dc.contributor.author | Bée, V. | |
dc.contributor.author | Santana, M. | |
dc.contributor.author | Miller, D. | |
dc.contributor.author | Lalla, D. | |
dc.contributor.author | Slamon, D. | |
dc.date.accessioned | 2017-01-30T11:29:23Z | |
dc.date.available | 2017-01-30T11:29:23Z | |
dc.date.created | 2015-10-29T04:09:56Z | |
dc.date.issued | 2013 | |
dc.identifier.citation | Au, H. and Eiermann, W. and Robert, N. and Pienkowski, T. and Crown, J. and Martin, M. and Pawlicki, M. et al. 2013. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study. Oncologist. 18 (7): pp. 812-818. | |
dc.identifier.uri | http://hdl.handle.net/20.500.11937/12232 | |
dc.identifier.doi | 10.1634/theoncologist.2013-0091 | |
dc.description.abstract |
Background. This study aims to describe and compare health- related quality of life (HRQL) in patients with node-positive and high-risk node-negative HER2-positive early breast can-cer receiving adjuvant docetaxel and trastuzumab-based or docetaxel-based regimens alone. Methods. Eligible patients (n = 3,222) were randomly assigned to either four cycles of adjuvant doxorubicin and cyclophosphamide followed by four cycles of docetaxel (AC-T) or one of two trastu- zumab-containing regimens: adjuvant doxorubicin and cyclophos- phamidefollowed bydocetaxel plustrastuzumabadministeredfor1 year (AC-TH) or six cycles of docetaxel pluscarboplatin combined with trastuzumab administered for 1 year (TCH). The European Or-ganization for Research andTreatment of Cancer (EORTC)Qualityof Life Questionnaire C30 and BR-23 were administered at baseline, thestartofcycle4(mid),andtheendofchemotherapy(EOC),aswell as at 6,12, and 24 months after chemotherapy. Results. Compliance rates for the EORTC questionnaires were acceptable at 72%-93% of eligible patients out to the 12- month assessment. Systemic side effect (SE) change scores were significantly improved for TCH-treated patients com-pared with AC->TH and AC-T at EOC, suggesting improved tolerability. Physical functioning (PF) was only slightly worse at midpoint for those receiving TCH, compared with patients who were just starting on taxane in an AC-TH regimen, but was otherwise similar between arms. All treatment arms re-covered from the deterioration in SE, PF, and Global Health Scale scores by 1 year and median future perspective change scores continued to improve throughout treatment and fol-low-up. Conclusion. HRQL outcomes for adjuvant docetaxel and trastu- zumab-based regimens are favorable and support TCH as a more tolerable treatment option. © AlphaMed Press 2013. | |
dc.publisher | AlphaMed Press | |
dc.title | Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, her2-positive early breast cancer: Results from the BCIRG 006 study | |
dc.type | Journal Article | |
dcterms.source.volume | 18 | |
dcterms.source.number | 7 | |
dcterms.source.startPage | 812 | |
dcterms.source.endPage | 818 | |
dcterms.source.issn | 1083-7159 | |
dcterms.source.title | Oncologist | |
curtin.department | Centre for Population Health Research | |
curtin.accessStatus | Open access via publisher |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |